Indivior (NASDAQ:INDV) Shares Gap Down to $16.12

Indivior PLC (NASDAQ:INDV) shares gapped down prior to trading on Monday . The stock had previously closed at $16.12, but opened at $15.41. Indivior shares last traded at $15.53, with a volume of 95,809 shares changing hands.

Wall Street Analysts Forecast Growth

Separately, Craig Hallum assumed coverage on shares of Indivior in a report on Wednesday, April 3rd. They issued a “buy” rating and a $37.00 price objective on the stock.

Indivior Trading Down 3.0 %

The company has a debt-to-equity ratio of 23.50, a current ratio of 0.92 and a quick ratio of 0.74. The business’s 50 day simple moving average is $17.18 and its 200 day simple moving average is $18.09. The company has a market capitalization of $2.11 billion, a price-to-earnings ratio of 1,527.00 and a beta of 0.69.

Indivior (NASDAQ:INDV) last issued its quarterly earnings results on Thursday, April 25th. The company reported $0.37 earnings per share for the quarter, missing the consensus estimate of $0.38 by ($0.01). The company had revenue of $284.00 million for the quarter, compared to analyst estimates of $300.00 million. Indivior had a return on equity of 842.72% and a net margin of 0.44%. Research analysts anticipate that Indivior PLC will post 2 EPS for the current year.

Institutional Inflows and Outflows

A number of institutional investors and hedge funds have recently made changes to their positions in INDV. Chilton Investment Co. Inc. acquired a new stake in Indivior in the fourth quarter valued at about $263,000. ADAR1 Capital Management LLC acquired a new stake in shares of Indivior in the 4th quarter valued at approximately $368,000. Cannon Global Investment Management LLC acquired a new position in Indivior during the first quarter worth $563,000. Campbell & CO Investment Adviser LLC raised its position in Indivior by 2.8% in the fourth quarter. Campbell & CO Investment Adviser LLC now owns 37,948 shares of the company’s stock worth $573,000 after acquiring an additional 1,037 shares in the last quarter. Finally, Forsta AP Fonden acquired a new stake in Indivior in the first quarter valued at $641,000. 60.33% of the stock is currently owned by institutional investors and hedge funds.

About Indivior

Indivior PLC, together with its subsidiaries, engages in the development, manufacture, and sale of buprenorphine-based prescription drugs for the treatment of opioid dependence and co-occurring disorders in the United States, the United Kingdom, and internationally. The company develops medicines to treat substance use disorders, serious mental illnesses, and opioid overdose.